AI Article Synopsis

  • - The study highlights the rapid growth in understanding FET::CREB fusion mesenchymal tumors, which now includes aggressive neoplasms not classified by WHO, specifically focusing on newly reported intra-abdominal and extra-abdominal cases with specific fusions like EWSR1::CREM and FUS::CREM.
  • - Nine additional tumors were analyzed, involving various locations and a wide age range for patients, with treatment primarily consisting of radical surgery and some receiving additional chemotherapy or radiation.
  • - The aggressive nature of these tumors is emphasized, with follow-up showing significant disease progression in some patients, while also noting similarities in immunophenotype across tumor subtypes, indicating a broader classification of potentially dangerous neoplasms.

Article Abstract

With the wide use of RNA sequencing technologies, the family of FET::CREB fusion mesenchymal neoplasms has expanded rapidly to include potentially aggressive neoplasms, not fitting any well established WHO entity. Recently, a group of intra-abdominal FET(EWSR1/FUS)::CREB(CREM/ATF1) fused unclassified neoplasms has been reported followed by recent recognition of an analogous extra-abdominal category of unclassified neoplasms carrying EWSR1::ATF1 fusions. We describe 9 additional tumors (5 extra-abdominal and 4 abdominal) carrying an EWSR1::CREM (n = 8) and FUS::CREM (n = 1) fusion. Patients were 7 females and 2 males aged 10 to 75 years (median, 34). Extra-abdominal tumors originated in the head and neck (2 sinonasal, 1 orbital) and soft tissues (1 gluteal, 1 inguinal). Abdominal tumors involved stomach (2), mesentery (1), and kidney (1). Tumor size ranged from 3.5 to 11 cm (median, 6). Treatment was radical surgery with (5) or without (2) neo/adjuvant radio/chemotherapy. Extended follow-up of 5 patients (21-52 months; median, 24) showed an aggressive course in two (40%); one died of disseminated metastases 52 months after several intensified chemotherapy regimens, and one was alive with progressive abdominal disease at 21 months. The immunophenotype of the two subcohorts was significantly overlapping with variable expression of EMA (7 of 8), keratin AE1/AE3 (5 of 9), CD99 (4 of 7), MUC4 (2 of 8), ALK (3 of 8), synaptophysin (3 of 9), chromogranin (1 of 8), CD34 (3 of 6), CD30 (1 of 6), PAX8 (1 of 7), and inhibin (1 of 7), but no reactivity with desmin (0 of 8), S100 (0 of 8), and SOX10 (0 of 8). This series further solidifies the notion that FET::CREB fusions are not limited to the triad of angiomatoid fibrous histiocytoma, clear cell sarcoma, and malignant gastrointestinal neuroectodermal tumor, but characterize an emerging family of potentially aggressive neoplasms occurring at both intra- and extra-abdominal sites. These tumors underscore the promiscuity of the FET::CREB fusions and highlight the pivotal role of phenotype-oriented classification of these neoplasms that share the same genotype, still featuring significant biological and behavioral distinctness.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666796PMC
http://dx.doi.org/10.1007/s00428-024-03917-2DOI Listing

Publication Analysis

Top Keywords

fusion mesenchymal
8
mesenchymal neoplasms
8
aggressive neoplasms
8
unclassified neoplasms
8
fetcreb fusions
8
neoplasms
7
extra-abdominal
5
extra-abdominal intra-abdominal
4
intra-abdominal fetcrem
4
fetcrem fusion
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!